Instil Bio Inc. News
Latest updates and market news for TIL
3 news
Jan 6 - Jan 12, 2026
Page 1
MT Newswires
Instil Bio Says Subsidiary Decided to Discontinue Clinical Development of AXN-2510; Shares Fall Pre-Bell
📉
AI Sentiment
Negative
2/10
GlobeNewswire
Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco
📉
AI Sentiment
Negative
2/10
Share this news page